Savara Inc Available-for-sale Securities, Amortized Cost Basis
Savara Inc (SVRA) had Available-for-sale Securities, Amortized Cost Basis of $59.06 million as of 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2020-11-05
- 2020-09-30: Available-for-sale Securities, Amortized Cost Basis $59.06M.
- 2020-06-30: Available-for-sale Securities, Amortized Cost Basis $52.34M.
- 2020-03-31: Available-for-sale Securities, Amortized Cost Basis $70.41M.
- 2019-12-31: Available-for-sale Securities, Amortized Cost Basis $71.91M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2020-09-30 | $59.06M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $52.34M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $70.41M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $71.91M 10-Q · filed 2020-11-05 |
| 2019-09-30 | $88.39M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $94.79M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $79.49M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $86.56M 10-K · filed 2020-03-12 |
| 2018-09-30 | $87.12M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $51.18M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $62.93M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $72.24M 10-K · filed 2019-03-13 |
| 2017-09-30 | $33.48M 10-Q · filed 2017-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |